<DOC>
	<DOCNO>NCT00028925</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial compare effectiveness combination chemotherapy without filgrastim treat patient extensive-stage small cell lung cancer previously treat .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Filgrastim Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine tolerability topotecan carboplatin without filgrastim ( G-CSF ) patient extensive stage small cell lung cancer . - Determine response survival rate patient treat regimen . OUTLINE : This multicenter study . The first 12 patient assign 1 2 treatment regimen ( 6 per regimen ) . The next 33 patient receive treatment base toxicity experience first 12 . Regimen A : - Patients receive oral topotecan daily day 1-5 , carboplatin IV 30 minute day 5 , filgrastim ( G-CSF ) subcutaneously daily begin day 6 7 continue 10 day blood count recover . - Patients evaluate first 3-week course chemotherapy . If patient experience unacceptable toxicity febrile neutropenia , 1 patient experience absolute neutrophil count less 500/mm3 5 day , next 6 patient begin treatment regimen B . Otherwise , patient receive treatment regimen A . Regimen B : - Patients receive topotecan carboplatin regimen A . - Patients evaluate first 3-week course chemotherapy . If patient experience unacceptable toxicity febrile neutropenia , next 33 patient receive treatment regimen B ; otherwise , patient receive treatment regimen A . Treatment patient repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients disease progression limit CNS interrupt chemotherapy whole-brain radiotherapy ( WBRT ) . Once WBRT complete , chemotherapy resume . Quality life assess baseline begin course chemotherapy . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 49 patient accrue study within 13.5 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm extensive stage small cell lung cancer Previously untreated chemotherapy No mixed histology Metastatic disease outside chest Contralateral supraclavicular hilar node include single radiation port OR Cytologically proven malignant pleural effusion Measurable disease No untreated CNS metastasis CNS metastasis treat wholebrain radiotherapy ( WBRT ) allow completion WBRT PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : AST great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Bilirubin great 1.5 time ULN OR Direct bilirubin great ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular : No uncontrolled angina pectoris No congestive heart failure within past 3 month unless ejection fraction great 40 % No uncontrolled cardiac arrhythmia No myocardial infarction within past 3 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinically significant infection No hypersensitivity E. coliderived proteins No malignancy within past 3 year except nonmelanoma skin cancer , carcinoma situ cervix , localized prostate cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 5 year since prior chemotherapy another malignancy No prior nitrosoureas Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior thoracic radiotherapy At least 1 day since prior palliative radiotherapy ( except chest ) No 3 fraction chest superior vena cava syndrome allow No concurrent radiotherapy ( include thoracic radiotherapy ) Surgery : More 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>